89bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Accretion of discounts on marketable securities, net of amortization of premiums
Amortization of debt issuance costs
Amortization of debt discount and accretion of deferred debt costs
Loss on extinguishment of debt
Noncash operating lease expense
Depreciation
Other
Deferred tax assets

Changes in operating assets and liabilities:
Prepaid and other assets
Accounts payable
Accrued expenses
Operating lease liabilities
Other non-current liabilities
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants in public offerings, net of issuance costs
Proceeds from issuance of common stock in at-the-market public offerings, net of issuance costs
Proceeds from term loan facility, net of issuance costs
Proceeds from issuance of common stock upon exercise of common stock warrants
Payment of debt issuance costs
Proceeds from issuance of common stock upon exercise of stock options
Proceeds from issuance of common stock under employee stock purchase plan
ESPP Purchases
Total proceeds from issuance of common stock under employee stock purchase plan

Payments of deferred offering costs
Payments for taxes related to net share settlement upon vesting of restricted stock units
Repayment of term loan
Net cash provided by financing activities

Net change in cash and cash equivalents, and restricted cash
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash and cash equivalents
Restricted cash
Supplemental disclosures of cash information:
Cash paid for interest
Cash paid for income taxes
Cash paid for amounts included in the measurement of lease liabilities

Supplemental disclosures of noncash information:
Unpaid offering costs included in accrued expenses
Right-of-use assets obtained in exchange for new operating lease liabilities
Remeasurement of lease liability and right of use asset in connection with lease modification
Issuance of common stock warrant in connection with term loan facility
Issuance of common stock warrants in connection with term loans

Comments